AI drug discovery
Mapping the layer of biology where a lot of disease actually lives
An Arc Institute atlas maps where 67 proteins grab onto RNA, opening the least-charted of biology's three control layers.

Efthymios Vogiatzis · · 2 min read
Arc Institute, with Biohub and the University of California, San Francisco, posted an atlas this week of where proteins grab onto RNA.
It covers 67 cancer-associated RNA-binding proteins and maps more than 9 million binding sites at single-letter resolution. Humans have roughly 1,500 of these proteins, about 7.5% of all our protein-coding genes, and they decide which messages in a cell get read, held or destroyed.
The trick is consistency: every protein gets the same small tag and goes through one identical pulldown, with infrared detection instead of radioactive labels, so differences in the data reflect biology rather than method.
It's a preprint, not yet peer reviewed. It covers 67 of around 1,500 proteins, the tag could nudge how a protein behaves, and the work was done in human cell lines, so binding may differ in living tissue.
Think about the arc here. We sequenced the genome, the letters. Then we mapped where proteins bind DNA, the first layer of control. This is the next layer down: where proteins bind RNA, after the gene is read but before the protein is made. That middle layer is where a lot of disease actually lives, and it has been the least mapped of the three.
Each layer we make legible becomes the training ground for the next generation of models. This one opens a layer that was mostly dark.
Sources
- Arc Institutehttps://arcinstitute.org/news/eclair-clip
- bioRxiv preprint (not yet peer reviewed)https://www.biorxiv.org/content/10.64898/2026.10.12.758580v1
- Note: fresh preprint; no independent newsroom coverage located at time of writing.

Efthymios Vogiatzis
Efthymios Vogiatzis is a pharmacist turned AI and data product leader, and the founder of VE1 Advisory in Vienna. He has led AI, data and analytics work across life sciences, biopharmaceuticals, insurance and industrial technology.
Start a conversationField notes by email.
A new essay about once a month on AI, data integrity and the people side of change.
Keep reading
21 October 2026 · Operations · 2 min read
The quiet half of biotech: scaling it next to a sugar mill
A Brevel and Wave Group plant jumps from a 5,000-litre tank to 300,000 litres, on a feedstock sitting next door. Scale-up is the half that decides whether biology reaches a shelf.
September 2026 · AI drug discovery · LinkedIn
What a pharmacist sees in the AI pipeline
The habits that keep data honest when the model moves faster than the audit trail.
